Skip to content
  • Clinical Studies
  • Pharma SOP’s
  • Pharma tips
  • Pharma Books
  • Stability Studies
  • Schedule M

Pharma GMP

Your Gateway to GMP Compliance and Pharmaceutical Excellence

  • Home
  • Quick Guide
  • GMP Failures & Pharma Compliance
    • Common GMP Failures
    • GMP Documentation & Records Failures
    • Cleaning & Sanitation Failures in GMP Audits
    • HVAC, Environmental Monitoring & Cross-Contamination Risks
  • Toggle search form

In-Process Checks During Granulation: Moisture, Endpoint and Sieving

Posted on November 25, 2025November 25, 2025 By digi


In-Process Checks During Granulation: Moisture, Endpoint and Sieving

Comprehensive Step-by-Step Guide to Granulation Process Controls in Tablet Manufacturing

The granulation step in tablet manufacturing represents a critical phase that directly influences the quality, consistency, and performance of the final solid dosage form. Implementing robust granulation process controls in tablet manufacturing is key to ensuring that drug products meet their predefined quality attributes and regulatory expectations from agencies such as FDA, EMA, and MHRA.

This article provides a detailed, step-by-step GMP tutorial guide that focuses on essential in-process checks during granulation. The focus is made on three primary aspects: moisture content, endpoint detection, and screen integrity. These parameters critically influence granule characteristics, downstream processability, and tablet quality attributes such as hardness, disintegration, and dissolution.

1. Overview of Granulation Process Controls in Tablet Manufacturing

Granulation is the process of particle enlargement by agglomerating smaller primary particles into granules, which improves flowability, compressibility, and homogeneity of blends. Two main granulation techniques are prevalent in pharma: wet granulation and dry granulation. Regardless of method, precise control and monitoring are imperative throughout.

Quality-by-Design (QbD) principles and risk-based approaches strongly recommend establishing well-defined in-process controls to mitigate variability and ensure batch-to-batch consistency. These controls must be validated and documented in accordance with 21 CFR Part 211, EU GMP Annex 15, and PIC/S PE 009 guidelines.

The primary parameters for granulation process controls include:

  • Moisture content: Influences granule plasticity and strength; critical for endpoint determination.
  • Endpoint detection: Ensures granules have achieved optimal size and properties avoiding overwetting or underwetting.
  • Screen integrity or sieving checks: Maintains granule size uniformity and removes fines or oversize particles to achieve consistent tablet weight and dissolution.
Also Read:  Inspection Expectations for Dedicated Equipment Documentation

Each parameter requires a structured monitoring approach and appropriate analytical techniques aligned with GMP expectations for in-process control sampling and testing frequency.

2. Step 1: Establishing Moisture Content Control during Granulation

Moisture level in granules significantly impacts technological performance. Excess moisture can cause capping or lamination during compression, while insufficient moisture compromises granule binding and compressibility.

2.1 Understanding Moisture Content as a Critical Quality Attribute

Moisture content controls are especially critical in wet granulation processes involving liquid binders. It governs the adhesion and plasticity of granules. Target moisture levels are typically established during process development and confirmed in validation batches. Operating outside this range can introduce variability.

2.2 Recommended Sampling and Testing Methods

Sampling should be representative and performed at defined process stages, typically at the granulator discharge or immediate pre-drying step. Common moisture determination techniques compliant with GMP include:

  • Loss-on-Drying (LOD) using validated moisture analyzers
  • Karl Fischer Titration for formulations sensitive to heat
  • Near-Infrared Spectroscopy (NIR) coupled with multivariate models for real-time monitoring

Note that moisture analyzers used must be calibrated and verified per internal calibration policy. Sampling frequency is generally every 30 minutes or after significant process parameter changes. All sampling and measuring activities must follow written procedures ensuring traceability.

2.3 Acceptance Criteria and Documentation

Acceptance limits for moisture content should be justified scientifically and based on process characterization. Trending of moisture values supports batch release decisions and root cause investigations if deviation occurs.

Best Practice: Integrate moisture content data within in-process documentation such as batch manufacturing records (BMRs) and electronic systems to assure compliance with data integrity principles.

3. Step 2: Endpoint Detection of Granulation – Ensuring Process Completeness

Precise determination of the granulation endpoint is essential to achieving granules with required size, density, and moisture. Premature endpoint results in weak granules while prolonged granulation causes overwetting and agglomeration, negatively affecting downstream processability and tablet quality.

3.1 Defining Endpoint Detection Parameters

Endpoint criteria can include physical, mechanical, or process variables such as:

  • Torque or motor load on the granulator impeller
  • Paddle speed and power consumption parameters
  • Granule particle size distribution (PSD)
  • Moisture content at various granulation stages
Also Read:  Inspection Cases: Misuse of Status Labels Leading to Serious Deviations

Modern granulators may utilize process analytical technology (PAT) tools, including in-line NIR or image analysis, for real-time monitoring to define endpoint dynamically.

3.2 Stepwise Procedure for Endpoint Determination

  1. Establish baseline data: Collect torque and moisture data during small-scale and pilot batches.
  2. Develop empirical models: Correlate impeller torque with granule strength and moisture content.
  3. Set control limits: Define upper and lower alarm limits to detect endpoint precisely.
  4. Train operators: Ensure operators understand the significance of endpoint detection and actions required.
  5. Perform routine monitoring: Record torque/load data continuously or at predefined intervals during granulation.
  6. Sample testing: Conduct particle size analysis or moisture testing immediately on suspected endpoint batches.
  7. Confirm endpoint: Corroborate physical testing results with process parameters before proceeding.

3.3 Managing Deviations and Out-of-Specification Results

If endpoint criteria are not met or granules do not exhibit expected properties, a predefined deviation handling procedure should be activated. This includes:

  • Reexamining process parameters for anomalies
  • Increasing or decreasing wet massing time under documented conditions
  • Implementing root cause analysis
  • Documenting corrective actions per MHRA GMP guidelines

4. Step 3: Screen Integrity and Sieving – Ensuring Granule Uniformity

Post-granulation sieving and screening maintain size uniformity, remove oversized agglomerates and fines, and ensure granules meet particle size specifications critical to tablet weight and content uniformity.

4.1 Importance of Screen (Sieve) Integrity in Granulation

The screen integrity check guarantees that the mesh used in screening is free from tears, holes, or blockages. Faulty screening may result in non-uniform granule size distribution, affecting flow and compression uniformity crucial for GMP compliance.

4.2 Stepwise SOP for Screening and Integrity Checks

  1. Prior to granulation: Inspect screen meshes visually and perform physical integrity tests.
  2. During sieving: Monitor for clogging or wear, and ensure the granulator discharge passes through the correct screen size.
  3. Sampling granules: Collect representative samples post-screening to analyze particle size distribution (PSD) using sieve analysis or laser diffraction.
  4. Routine screen maintenance: Clean and inspect screens after each batch or at defined intervals per risk assessment.
  5. Document results: Record screen integrity checks and PSD results in batch documentation.
Also Read:  Granulation SOP Template: Critical Steps and Documentation Points

4.3 Acceptance Criteria and Regulatory Expectations

Acceptance limits for granule size are generally defined based on formulation and process development studies. Consistent screen integrity checks assure compliance with regulatory expectations outlined in ICH Q7 and PIC/S guidelines for batch control and in-process monitoring.

Failure to maintain screen integrity can trigger batch rejection or necessitate reprocessing. Therefore, preventive maintenance and thorough operator training are essential components of GMP compliance.

5. Integration of In-Process Control Data within Manufacturing Quality Systems

Data from monitoring moisture content, endpoint detection, and screen integrity must be integrated into manufacturing quality systems for effective batch release and continual improvement. The following practices are recommended:

  • Electronic Batch Records (EBR): Record all in-process test results digitally with audit trails to support data integrity principles.
  • Trend Analysis: Use statistical process control (SPC) tools to monitor process performance over time and identify drift or shifts early.
  • Deviation Management: Implement robust procedures for investigating out-of-specification in-process results, with documented CAPA.
  • Training and Competency: Regularly train operators and quality personnel in interpreting control results and taking appropriate corrective actions.
  • Validation and Revalidation: Incorporate in-process controls into process validation protocols and periodically revalidate based on process changes or trends.

These measures align with regulatory expectations such as those outlined in ICH Q10 for pharmaceutical quality systems and FDA’s Process Validation guidance.

Conclusion

Robust in-process controls during granulation underpin a scientifically sound, validated manufacturing process. By systematically monitoring and controlling moisture content, implementing stringent endpoint detection criteria, and ensuring reliable screen integrity, pharmaceutical manufacturers can assure high-quality granules and ultimately tablets that meet stringent regulatory and quality requirements.

Adopting a stepwise, GMP-compliant approach with comprehensive documentation, operator training, and integration within quality management systems positions manufacturers favorably for successful inspections and regulatory compliance across the US, UK, and EU markets.

Granulation Controls Tags:endpoint, granulation, moisture, pharmagmp, sieving

Post navigation

Previous Post: Granulation Deviations: Lumps, Over-Wet Mass and Poor Flow
Next Post: Granulation Process Controls for Robust Tablet Manufacturing

Quick Guide

  • GMP Basics
    • Introduction to GMP
    • What is cGMP?
    • Key Principles of GMP
    • Benefits of GMP in Pharmaceuticals
    • GMP vs. GxP (Good Practices)
  • Regulatory Agencies & Guidelines
    • WHO GMP Guidelines
    • FDA GMP Guidelines
    • MHRA GMP Guidelines
    • SCHEDULE – M – Revised
    • TGA GMP Guidelines
    • Health Canada GMP Regulations
    • NMPA GMP Guidelines
    • PMDA GMP Guidelines
    • EMA GMP Guidelines
  • GMP Compliance & Audits
    • How to Achieve GMP Certification
    • GMP Auditing Process
    • Preparing for GMP Inspections
    • Common GMP Violations
    • Role of Quality Assurance
  • Quality Management Systems (QMS)
    • Building a Pharmaceutical QMS
    • Implementing QMS in Pharma Manufacturing
    • CAPA (Corrective and Preventive Actions) for GMP
    • QMS Software for Pharma
    • Importance of Documentation in QMS
    • Integrating GMP with QMS
  • Pharmaceutical Manufacturing
    • GMP in Drug Manufacturing
    • GMP for Biopharmaceuticals
    • GMP for Sterile Products
    • GMP for Packaging and Labeling
    • Equipment and Facility Requirements under GMP
    • Validation and Qualification Processes in GMP
  • GMP Best Practices
    • Total Quality Management (TQM) in GMP
    • Continuous Improvement in GMP
    • Preventing Cross-Contamination in Pharma
    • GMP in Supply Chain Management
    • Lean Manufacturing and GMP
    • Risk Management in GMP
  • Regulatory Compliance in Different Regions
    • GMP in North America (FDA, Health Canada)
    • GMP in Europe (EMA, MHRA)
    • GMP in Asia (PMDA, NMPA, KFDA)
    • GMP in Emerging Markets (GCC, Latin America, Africa)
    • GMP in India
  • GMP for Small & Medium Pharma Companies
    • Implementing GMP in Small Pharma Businesses
    • Challenges in GMP Compliance for SMEs
    • Cost-effective GMP Compliance Solutions for Small Pharma Companies
  • GMP in Clinical Trials
    • GMP Compliance for Clinical Trials
    • Role of GMP in Drug Development
    • GMP for Investigational Medicinal Products (IMPs)
  • International GMP Inspection Standards and Harmonization
    • Global GMP Inspection Frameworks
    • WHO Prequalification and Inspection Systems
    • US FDA GMP Inspection Programs
    • EMA and EU GMP Inspection Practices
    • PIC/S Role in Harmonized Inspections
    • Country-Specific Inspection Standards (e.g., UK MHRA, US FDA, TGA)
  • GMP Blog

Latest Posts

  • GMP-cGMP Regulations & Global Standards
    • FDA cGMP Regulations for Drugs & Biologics
    • cGMP Requirements for Pharmaceutical Manufacturers
    • ICH Q7 and API GMP Expectations
    • Global & ISO-Based GMP Standards
    • GMP for Medical Devices & Combination Products
    • GMP for Pharmacies & Hospital Pharmacy Settings
  • Applied GMP in Pharma Manufacturing & Operations
    • GMP for Pharmaceutical Drug Product Manufacturing
    • GMP for Biotech & Biologics Manufacturing
    • GMP Documentation
    • GMP Compliance
    • GMP for APIs & Bulk Drugs
    • GMP Training
  • Computer System Validation (CSV) & GxP Computerized Systems
    • CSV Fundamentals in Pharma & Biotech
    • FDA CSV Guidance & 21 CFR Part 11 Alignment
    • GAMP 5 & Risk-Based Validation Approaches
    • CSV in Pharmaceutical & GxP Industries (Use-Cases & System Types)
    • CSV Documentation
    • CSV for Regulated Equipment & Embedded Systems
  • Data Integrity & 21 CFR Part 11 Compliance
    • Data Integrity Principles in cGMP Environments
    • FDA Data Integrity Guidance & Expectations
    • 21 CFR Part 11 – Electronic Records & Signatures
    • Data Integrity in GxP Computerized Systems
    • Data Integrity Audits
  • Pharma GMP & Good Manufacturing Practice
    • FDA 483, Warning Letters & GMP Inspections
    • Data Integrity, ALCOA+ & Part 11 / Annex 11
    • Process Validation, CPV & Cleaning Validation
    • Contamination Control & Annex 1
    • PQS / QMS / Deviations / CAPA / OOS–OOT
    • Documentation, Batch Records & GDP
    • Sterility, Microbiology & Utilities
    • CSV, GAMP 5 & Automation
    • Dosage-Form–Specific GMP (Solids, Liquids, Sterile, Topicals)
    • Supply Chain, Warehousing, Cold Chain & GDP
Widget Image
  • Never Assign Batch Release Responsibilities to Non-QA Personnel in GMP

    Never Assign Batch Release Responsibilities… Read more

  • Manufacturing & Batch Control
    • GMP manufacturing process control
    • Batch Manufacturing record requirements
    • Master Batch record template for pharmaceuticals
    • In Process control checks in tablet manufacturing
    • Line clearance procedure before batch start
    • Batch reconciliation in pharmaceutical manufacturing
    • Yield reconciliation GMP guidelines
    • Segregation of different strength products GMP
    • GMP controls for high potency products
    • Cross Contamination prevention in manufacturing
    • Line clearance checklist for production
    • Batch documentation review before qa release
    • Process parameters control limits in pharma
    • Equipment changeover procedure GMP
    • Batch manufacturing deviation handling
    • GMP expectations for batch release
    • In Process sampling plan for tablets
    • Visual inspection of dosage forms GMP requirements
    • In Process checks for filled vials
    • Startup and Shutdown procedure for manufacturing line
    • GMP requirements for blending and mixing operations
    • Process Control strategy in pharmaceutical manufacturing
    • Uniformity of dosage units in process controls
    • GMP checklist for oral solid dosage manufacturing
    • Process Control
    • Batch Documentation
    • Master Batch Records
    • In-Process Controls
    • Line Clearance
    • Yield & Reconciliation
    • Segregation & Mix-Ups
    • High Potency Products
    • Cross Contamination Control
    • Line Clearance
    • Batch Review
    • Process Parameters
    • Equipment Changeover
    • Deviations
    • Batch Release
    • In-Process Sampling
    • Visual Inspection
    • In-Process Checks for Vials
    • Start-Up & Shutdown
    • Blending & Mixing
    • Control Strategy
    • Dosage Uniformity
    • Hold Time Studies
    • OSD GMP Checklist
  • Cleaning & Contamination Control
  • Warehouse & Material Handling
    • Warehouse GMP
    • Material Receipt
    • Sampling
    • Status Labelling
    • Storage Conditions
    • Rejected & Returned
    • Reconciliation
    • Controlled Drugs
    • Dispensing
    • FIFO & FEFO
    • Cold Chain
    • Segregation
    • Pest Control
    • Env Monitoring
    • Palletization
    • Damaged Containers
    • Stock Verification
    • Sampling & Weighing Areas
    • Issue to Production
    • Traceability
    • Printed Materials
    • Intermediates
    • Cleaning & Housekeeping
    • Status Tags
    • Warehouse Audit
  • QC Laboratory & Testing
    • Analytical Method Validation
    • Chromatography Systems
    • Dissolution Testing
    • Assay & CU
    • Impurity Profiling
    • Stability & QC
    • OOS Investigations
    • OOT Trending
    • Sample Management
    • Reference Standards
    • Equipment Calibration
    • Instrument Qualification
    • LIMS & Electronic Data
    • Data Integrity
    • Microbiology QC
    • Sterility & Endotoxin
    • Environmental Monitoring
    • QC Documentation
    • Results Review
    • Method Transfer
    • Forced Degradation
    • Compendial Methods
    • Cleaning Verification
    • QC Deviations & CAPA
    • QC Lab Audits
  • Manufacturing & In-Process Control
    • Batch Manufacturing Records
    • Batch Manufacturing Records
    • Line Clearance
    • In-Process Sampling & Testing
    • Yield & Reconciliation
    • Granulation Controls
    • Blending & Mixing
    • Tablet Compression Controls
    • Capsule Filling Controls
    • Coating Process Controls
    • Sterile & Aseptic Processing
    • Filtration & Sterile Filtration
    • Visual Inspection of Parenteral
    • Packaging & Labelling Controls
    • Rework & Reprocessing
    • Hold Time for Bulk & Intermediates
    • Manufacturing Deviations & CAPA
  • Documentation, Training & QMS
    • SOP & Documentation Control
    • Training & Competency Management
    • Change Control & QMS Lifecycle
    • Internal Audits & Self-Inspection
    • Quality Metrics, Risk & Management Review
  • Production SOPs
  • QC Laboratory SOPs
    • Sample Management
    • Analytical Methods
    • HPLC & Chromatography
    • OOS & OOT
    • Data Integrity
    • Documentation
    • Equipment
  • Warehouse & Materials SOPs
    • Material Receipt
    • Sampling
    • Storage
    • Dispensing
    • Rejected & Returned
    • Cold Chain
    • Stock Control
    • Printed Materials
    • Pest & Housekeeping
  • Cleaning & Sanitization SOPs
  • Equipment & Qualification SOPs
  • Documentation & Data Integrity SOPs
  • Deviation/OOS/CAPA SOPs
    • Deviation Management
    • Root Cause
    • CAPA
    • OOS/OOT
    • Complaints
    • Recall
  • Training & Competency SOPs
    • Training System
    • Role-Based Training
    • OJT
    • Refresher Training
    • Competency
  • QA & QMS Governance SOPs
    • Quality Manual
    • Management Review
    • Internal Audit
    • Risk Management
    • Vendors & Outsourcing
  • About Us
  • Privacy Policy & Disclaimer
  • Contact Us

Copyright © 2025 Pharma GMP.

Powered by PressBook WordPress theme